NE
Nephros, Inc.
NEPH · NASDAQ
$4.38 +0.11% (+$0.00)
1M -0.68%
Market Cap $47.5M
P/E Ratio 27.36x
Div. Yield -
ROE 16.20%
Bulios Fair Price
$2.72
37.8% downside
Current Price
$4.38
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NEPH is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
42 /100
Fair P/B 3.97x
P/S 2.29x
P/E 27.36x
Growth
100 /100
Growing Book val. growth 22.19%
Rev. growth 23.50%
FCF growth N/A
Profitability
41 /100
Moderate FCF margin 3.19%
Op. margin 7.92%
Gross margin 60.31%
Quality
79 /100
Excellent Asset turnover 1.31x
ROA 11.01%
ROIC 12.67%
Debt
100 /100
Low Net debt/EBITDA -2.11x
Int. coverage 1,694.00x
Debt/Equity 0.07x
Stability
27 /100
Unstable Profitable years 2
EPS volatility 796.56%
Beta 1.56x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NEPH
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Robert Banks
Employees
36
Headquarters
South Orange
Upcoming events
05 NOV
Earnings
Upcoming earnings report